

REFERENCES

- Alfaleh FZ, Hadad Q, Khuroo MS, et al. (2004):** Peginterferon alpha-2b plus 40. ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. *Liver Int*; 24(6):568-74.
- Alter MJ (2006):** The epidemiology of viral hepatitis and HIV co infection. *Journal of hepatology* 44: 56-59
- Alter MJ, Kruszon-Moran D, Nainan OV, et al. (1999):** The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med* 341: 556-562.
- Antonelli A, Ferri C, Pampana A, et al. (2004) :** Thyroid disorders in chronic hepatitis C. *Am J Med* 117 (1):10-3.
- Asselah T, Rubbia-Brandt L, Marcellin P, et al. (2006):** Steatosis in chronic hepatitis C: why does it really matter? *Gut*. 2006; 55(1):123-30.
- Bacon BR (2000):** Treatment of patients with hepatitis C and normal serum aminotransferase levels. *Hepatology* 36 (5 Suppl 1): S179-S184.
- Bacon BR and Shiffman ML (2009):** Phase 2 randomized, double-blind, placebo- controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 patients: Interim analysis shows increase in EVR. *J Hepatol* 50S: 381.

- Berg T, von Wagner M, Nasser S, et al (2008):** Tailored Treatment for Hepatitis C. Clin Liver Dis 12: 507–528.
- Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Geriach T et al. (2006):** Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130: 1086-1097.
- Bini EJ and Mehandru S. (2005):** Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels. Aliment Pharmacol Ther 2005; 23:777–785.
- Booth J, O'Grady J and Neuberger J (2001):** Clinical guidelines of the management of hepatitis C. Gut 49 (Suppl I): 1-21
- Brau N, Bini EJ, Currie S, et al. (2006):** Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin. J Viral Hepat 13: 242–249.
- Bressler BL, Guindi M, Tomlinson G et al. (2003):** High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38: 639–644.
- Chevaliez S and Pawlotsky JM (2007):** Interferon-based therapy of hepatitis C. Adv Drug Deliv Rev 59: 1222–1241.

- Conjeevaram HS, Fried MW, Jeffers LJ, et al. (2006):** Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. *Gastroenterology* 131: 470–477.
- Conjeevaram HS, Kleiner DE, Everhart JE, et al. (2007):** Race, insulin resistance and hepatic steatosis in chronic hepatitis C. *Hepatology* 45:80–87.
- Dalgard O, Bjoro K, Ring-Larsen H, et al. (2008):** Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. *Hepatology* 47: 35–42.
- Datta SD, Armstrong GL, Roome AJ et al., (2003):** Blood exposure and hepatitis C virus infections among emergency groups. *Arch intern med* 163: 2605-2610.
- Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J (2003):** Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology* 38: 645-652.
- Desmet VJ, Roskams T (2004):** Cirrhosis reversal: a duel between dogma and myth. *J Hepatol* 40(5):860-7.
- Di Bisceglie AM (2000):** Natural history of hepatitis C: its impact on clinical management. *Hepatology* 31: 1014-1018.
- Di Bisceglie AM (2006):** Hepatitis C. *Clinical Hepatology* 2:235-248.

- Dienstag JL (2002):** The role of liver biopsy in chronic hepatitis C. *Hepatology* 36 (Suppl): S152-S160.
- Distante S, Bjoro K, Hellum KB et al. (2002):** Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. *Liver*; 22:269–275.
- Doss W, Esmat G, El-sayed M et al. (2008):** Egyptian national control Strategy for viral hepatitis. National committee for control of viral hepatitis. Agency national de recherche sur le SIDA (ANRS) 6-12.
- Dries V, Odenthal M, Schirmacher P (2001):** Liver biopsy in chronic hepatitis C. Histopathology, molecular diagnostic analysis, and implications for therapeutic management. *Pathology* 22(6): 362-8.
- Dusheiko GM, Hezode C, Pol S, Goeser T, Bronowicki JP, Bourliere M, et al. (2008):** Treatment of chronic hepatitis C with telaprevir (TVR) in combination with peginterferon-alfa-2a with or without ribavirin: Further interim analysis results of the PROVE2 study. *Journal of Hepatology* 48: S26-S.
- El Makhzangy H, Esmat G, Said M, et al. (2009):** Response to pegylated interferon Alfa-2a and Ribavirin in chronic hepatitis C genotype 4. *Journal of Medical Virology* 81: 1576-1583.

- El-Serag HB, Hampel H, Rabeneck L et al., (2002):** Extrahepatic manifestations of hepatitis C among United States male veterans. *Hepatology* 36(6):1439-45.
- Everson GT, Hoefs JC, Seeff LB, et al. (2006):** Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. *Hepatology*; 44:1675–1684.
- Farci P, Strazzera R, Alter HJ, et al. (2002):** Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. *Proc Natl Acad Sci USA* 99:3081–3086.
- Fargion S, Fracanzani AL, Sampietro M, et al. (1997):** Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. *Eur J Gastroenterol Hepatol*; 9:497–503.
- Fattovich G, Stroffolini T, Zagni I, Donato F (2004):** Hepatocellular carcinoma in cirrhosis: incidence and risk factors *Gastroenterology* 127 (Suppl 1): S35: S50.
- Feld JJ, Hoofnagle JH (2005):** Mechanism of action of interferon and ribavirin in treatment of hepatitis C. *Nature* 436: 967-972.
- Ferenci P, Laferl H, Scherzer TM, et al. (2008):** Peginterferon Alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. *Gastroenterology* [Epub ahead of print].

- Ferri C, Zignego AL, Pileri SA (2002):** Cryoglobulins. *J. Clin Pathol* 55: 4-13.
- Fissell RB, Bragg-Gresham JL, Woods JD (2004):** Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. *Kidney Int* 65 (6): 2335.
- Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, et al. (2007):** Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C *Hepatology* 46: 640-648.
- Fracanzani AL, Conte D, Fraquelli M, et al. (2001):** Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. *Hepatology* ; 33:647–651.
- Frank C, Mohamed K, Strickland T, et al. (2000):** The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. *Lancet* 2000;355: 887–891.
- Fried MW, Jensen DM, Rodriguez-Torres, Nyberg LM, Di Bisceglie AM, Morgan TR, et al. (2008):** Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study of higher doses of peginterferon α -2a and ribavirin. *Hepatology* 48: 1033-1043.

- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. (2002):** Pegintereron alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 347: 975-982.
- Ghany G. Marc, Doris B. Strader, David L. Thomas, et al.(2009):** Diagnosis, Management, and Treatment of Hepatitis C: An Update. *Hepatology*, April; 49: 1335-1374.
- Gish RG, Arora S, Reddy KR, Nelson DR, O'Brien C, Xu Y, et al. (2007):** Virological response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2A: A randomized, phase 2 study. *Journal of Hepatology* 47: 51-59.
- Hadziyannis SJ, Seffe H Jr, morgan RT, et al. (2004):** Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C a randomized study of treatment duration and ribavin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 140: 346-55.
- Hasan F, Asker H, Al Khaldi J, et al. (2004):** Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. *Am J Gastroenterol*; 99:1733–1737.
- Hasan F, Asker H, AL Khaldi J, Siddique I, AL Ajmi M, Owaid S, Varghese R, Al-Nakib B (2004).** Pegintterferon alfa 2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. *Am J Gastroentterol* 99:1733 -7

- Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, Sentjens RE, Calleja JL, et al. (2004):** Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. *Gastroenterology* 127: 1347-1355.
- Hofer H, Osterreicher C, Jessner W, et al. (2004):** Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. *J Hepatol* 40: 1018–1022.
- Hoofnagle JH (2002):** Course and outcome of hepatitis C. *Hepatology* 36 (Supl 1): S21-S29.
- Hoofnagle JH, See LB (2006):** Peginterferon and ribavirin for chronic hepatitisC. *N Engl J Med* 355: 2444-2451.
- Horsmans Y, Berg T, Desager JP, Mueller T, Schott E, Fletcher SP, et al. (2005):** Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. *Hepatology* 42: 731.
- Hu KQ, Tong MJ (1999):** The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United states. *Hepatology* 29: 1311-1316.
- Hui JM, Kench J, Farrell GC, et al. (2002):** Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. *J Gastroenterol Hepatol* 17:873–881.

- Hwang SJ, Luo JC, Chu CW, et al. (2001):** Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. *J Gastroenterol Hepatol* 16: 190–195.
- Jacobi C, Wenkel H, Jacobi A, Korn K, Cursiefen C, Kruse FE(2007):** Hepatitis C and ocular surface disease. *Am J Ophthalmol* 144(5):705-711.
- Jacobson IM, Brown RS, McCone J, Black M, Albert C, Dragutsky MS, et al. (2007):** Impact of weight-basd ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. *Hepatology* 46: 982-990.
- Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. (2006):** Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α -2a (40 kd)/ribavirin therapy. *Hepatology* 43: 954-960.
- Jorquera F, Monte MJ, Guerra J, et al. (2005):** Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to antiviral treatment in chronic hepatitis C. *J Gastroenterol Hepatol* 20:547–554.
- Kamal S and Nasser (2008) I.** Hepatitis C genotype 4: what we know and we don't yet know. *Hepatology* 2008; 47: 1371-83.
- Kamal SM, El Kamary SS, Shardell MD, et al. (2007):** Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. *Hepatology* 46: 1732-1740.

- Kamal SM. (2009):** Hepatitis C genotype 4 therapy: increasing options and improving outcomes. *Liver Int* 29 Suppl 1:39-48.
- Kau A, Vermehren J and Sarrazin C (2008):** Treatment predictors of a sustained virologic response in hepatitis B and C. *Journal of Hepatology*; 49 :634–651.
- Kessel A., Rosner I., Zuckerman E. (2000):** Use of antikeratin antibodies to distinguish between rheumatoid arthritis and polyarthritis associated with hepatitis C infection. *J. Rheumatol* 2000; 27:610-2.
- Khuroo MS, Khuroo MS and Dahab ST. (2004):** Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. *Aliment Pharmacol Ther*; 20:931–938.
- Kleiner DE (2005):** The liver biopsy in chronic hepatitis C: A view from the other side of the microscope. *Semin Liver Dis* 25: 52-64.
- Knapp R G and Miller M C (1992):** Clinical Epidemiology and Biostatistics. National Medical Series (NMS) from Williams and Wilkins.
- Kumar D, Farrell GC, Fung C, et al (2002):** Hepatitis C virus genotype 3 is cytopathic to hepatocytes. Genotype-specific reversal of hepatic steatosis after sustained response to antiviral therapy. *Hepatology* 36: 1266- 1272.

- Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, et al. (2003):** An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. *Nature* 426: 186-189.
- Lauer G and Walker B (2001):** Hepatitis C Virus Infection. *N Engl J Med*, 345 (1): 41-52.
- Lavanchy D and McMahon B (2000):** Worldwide prevalence and
Lecube A, Hernandez C, Simo R, et al. (2007): Glucose abnormalities are an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. *Am J Gastroenterol*;102:2189–2195.
- Liang TJ, Rehermann B, Seeff LB, et al. (2000):** Pathogenesis, natural history, treatment, and prevention of hepatitis C. *Ann Int Med* 132: 296-305.
- Lindenbach BD, Rice CM (2005):** Unravelling hepatitis C virus replication from genome to function. *Nature* 436: 933-938.
- Males S, Gad RR, Esmat G et al. (2007):** Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C. *Antivir Ther*; 12(5):797-803
- Mangia A, Minerva N, Bacca D, et al. (2008):** Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. *Hepatology*; 47:43–50.
- Manns MP, McHutchinson JG, Gordon SC, et al. (2001):** Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial *lancet* 358: 958-965.

- Manns MP, McHutchison JG, Gordon SC, Rustgi VK, et al. (2001):** Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2a for initial treatment of chronic hepatitis C: a randomized trial. *Lancet*; 358:958-965.
- Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. (2001):** Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. *Lancet* 358: 958-965.
- McGuire BM, Julian BA, Bynon JS Jr, Cook WJ, King SJ, Curtis JJ, Accortt NA, Eckhoff DE (2006):** Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. *Ann Intern Med* 144 (10): 735-41.
- McHutchison JG, Dusheiko G, Shiffman ML, et al.(2007) :** Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. *N Engl J Med* 357: 2227-2236.
- McHutchison JG, Everson GT, Gordon SC, Jacobson I, Kaufman R, McNair L et al. (2007):** Results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naïve subjects with hepatitis C. *Journal of Hepatology* 48: S4-S.
- McHutchison JG, Poynard T, Pianko S, et al. (2000):** The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. *Gastroenterology*; 119:1317–1323.

- Missiha S, Heathcote J, Arenovich T, et al. (2007):** Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. *Am J Gastroenterol*; 102:2181-2188
- Mondelli M (2003):** Natural history of hepatitis C virus infection. *Journal of Biological Regulators and Homeostatic Agents* 17: 128-32.
- Nafeh MA, Medhat A, Shehata M, et al (2000):** Hepatitis C in community in upper Egypt: I. Cross- sectional survey. *Am J Trop Med Hgy* 63:236-241.
- Ortiz V, Berenguer M, Rayon JM, et al. (2002):** Contribution of obesity to hepatitis C-related fibrosis progression. *Am J Gastroenterol*; 97:2408–2414.
- Pascu M, Martus P, Hohne M, et al. (2004):** Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. *Gut* 53: 1345–1351.
- Pearlman BL, Ehleben C and Saifee S (2007):** Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. *Hepatology* 46: 1688–1694.

- Poynard T, McHutchison J, Goodman Z, et al. (2000):** Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. *Hepatology* 31: 211–218.
- Poynard T, Munteanu M, Ngo Y, Torres M, et al. (2006):** Diagnostic value of fibro-test with normal serum amino transferon. *Hepatology* 43: 374-375.
- Poynard T, Ratziu V, Charlotte F et al. (2001):** Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. *J Hepatol* 34: 730–739
- Poynard T, Ratziu V, McHutchison J, et al. (2003):** Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. *Hepatology* 38: 75-85.
- Ray Sc, Arthur RR, Carella A, et al. (2000):** Genetic epidemiology of hepatitis of C virus through Egypt. *J Infect Dis* 182 (3): 698-707.
- Reiser M, Hinrichsen H, Benhamou Y, Reesink HW, Wedemeyer H, Avendano C, et al. (2005):** Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C *Hepatology* 41: 832-835.

- Roberts EA and Yeung L (2002):** Maternal –infant Transmission of hepatitis C virus infection. *Hepatology*; 36:106-113.
- Roberts S, Cooksley G, Dore G, Robson R, Shaw D, Berns H, et al. (2007):** Viral load and ALT reductions associated with R1626 monotherapy, a novel nucleoside analog, in chronic hepatitis C genotype 1 patients. *Gastroenterology* 132: A779-A.
- Rodriguez -Torres M, Sulkowski M, Chung RT, et al. (2007):** Association of pre-treatment and on-treatment factors with rapid virological response in HCV genotype 1 infected patients treated with PEGIFn α -2a/RBV [abstract no. 1305]. *Hepatology* 2007; 46 (4 Suppl 1):817A.
- Rodriguez-Torres M, Sulkowski MS, Chung RT, et al. (2010)** Factors associated with rapid and early virologic response to peginterferon alfa-2a-ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. *Journal of Viral Hepatitis* 2010; 17(2): 139-147
- Romero-Gomez M, Del Mar Vilorio M, Andrade RJ, et al. (2005):** Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. *Gastroenterology*; 128: 636-641.
- Roulot D, Bourcier V, Grando V, et al. (2007):** Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. *J Viral Hepat* 14: 460-467.

- Sabry AA, Sobh MA, Sheaaashaa HA, et al.(2002)** Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. *Nephrol Dial Transplant* 17(11): 1924-30.
- Salama MM, Abou Gabal AK, Tharwa ES, et al.(2010):** Gamma glutamyl traspeptidase and alphafetoprotein: Are they predictors of treatment response in chronic hepatitis C patients? National liver institute, Menoufiya university 2010; 79-85.
- Salmeron J, Casado J, Rueda PM, et al. (2008):** Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin. *J Clin Virol*; 41:264–269.
- Samuel S Lee and Ayman A Abdo (2003):** Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon? *Journal of Antimicrobial Chemotherapy* 51: 487-491.
- Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M,Barcena R, et al. (2006):** Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. *Gastroenterology* 131: 451-460.
- Sarrazin C, Gartner BC, Sizmann D, et al. (2006):** Comparison of conventional PCR with real time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. *J Clin Microbiol* 44: 729–737.

- Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, et al. (2007):** Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. *Gastroenterology* 132: 1767-1777.
- Schiff E, Michael F and Willis C (2007):** Hepatitis C. Schiff's disease of the liver .Gary D.Tenth Edition, part 2.30: 819-834.
- Schiff E, Poordad E, Jacobson Il Flamm S, Bacon B, Lawitz E, et al. (2008):** Boceprevir (B) combination therapy in null responders (NR): Response dependent on interferon responsiveness. *Journal of Hepatology* 48: S46-S.
- Scott JD and Gretch DR (2007):** Molecular diagnostics of hepatitis C virus infection: a systematic review. *Jama* 297: 724-732.
- Seeff LB, Miller RN, Rabkin CS. (2000):** 45Years follow-up of hepatitis C virus infection in healthy young adults. *Ann Intern Med* 132: 105-11.
- Seeff LB., (2005):** Natural history of hepatitis C. *Hepatology. Rev.* 2: 88-96
- Shaheen AA and Myers RP (2007):** Diagnostic accuracy of the aspartate amino transferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systemic review. *Hepatology* 48 (3): 912-921.
- Shepard CW, Finelli L, Alter MJ (2005):** Global epidemiology of hepatitis c virus infection. *Lancet Infect. Dis* 5: 558-567.

Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. (2007): Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. *N Engl J Med* 357: 124-134.

Shiffman ML, SuterF, Bacon BR et al (2007): Peg interferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. *N Engl J Med* 357:124–134.

Shintani Y, Fujie H, Miyoshi H, et al. (2004): Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. *Gastroenterology* 126: 840–848.

Silva IS, Ferraz ML, Perez RM, et al. (2004): Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. *J Gastroenterol Hepatol* 19: 314–318.

Simmonds P, Bukh J, Combet C, Deléage G, et al. (2005): Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. *Hepatology* 42:962-973.

Singer ME and Younossi ZM (2001): Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. *Am J Med* 3: 614-621.

Steckelberg J (2007): Hepatitis C: How common is sexual transmission? Mayo Clinic Staff, Nov. 17. [www. Mayo Clinic.com /health/AN0070](http://www.MayoClinic.com/health/AN0070).

- Strader DB, Wright T, Thomas DL, Seeff LB (2004):** Diagnosis, management, and treatment of hepatitis C. American Association for the Study of Liver Diseases Practice Guideline. *Hepatology* 39:1147-1171.
- Strader DB, Wright T, Thomas DL, See LB (2004):** Diagnosis, management, and treatment of hepatitis C. *Hepatology* 39: 1147-1171.
- Thomas DL, See LB (2005):** Natural history of hepatitis C. *Clin Liver Dis* 9: 383-398.
- Villano S, Raible D, Harper D, Chandra P, Bazisottol L, Bichier G (2007):** Phase 1 evaluation of antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with different pegylated interferons in the treatment-naïve patients with chronic HCV. *Hepatology* 46: 815A.
- Von Wagner M, Huber M, Berg T (2005):** Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. *Gastroenterology* 129 (2): 522-7.
- Waked IA, Rewisha EA, Abd ELwahed AS,et al.(2009):** Early, end of treatment and sustained virological response of interferon plus ribavarin, does it differ in patients with chronic hepatitis c with normal versus elevated trasaminases? National liver institute, Menoufiya university 2009; 87-93

- Wakil A and Merezban Z (2006):** Hepatitis C in Egypt. In Egypt today magazine. HCV adovacte. WWW.HCV adovacte.org.
- Washington K, Wright K, Shyr Y, Hunter EB, et al. (2000):** Hepatic Stellate Cell Activation in Nonalcoholic Steatohepatitis and Fatty Liver. Hum Pathol Jul 31(7):822-8.
- Wasley A, Alter MJ (2000):** Epidemiology of hepatitis C: Geogrpahic differences and temporal trends. Semin Liver Dis 20: 1-16.
- Zeuzem S, Buti M, Ferenci P, Speri J, Horsmans Y, Cianciara J, et al. (2006):** Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44: 97-103.